Is QNCX or REPL more undervalued in 2026?

CirclFi compares Quince Therapeutics, Inc. (QNCX) and Replimune Group, Inc. (REPL) using 13 institutional-grade valuation models. QNCX has a Quality of Company score of 4.3/10 while REPL scores 4.4/10.

Which is a better buy — QNCX or REPL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do QNCX and REPL valuations compare?

QNCX at $1.15 and REPL at $8.69 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

QNCX vs REPL Valuation Comparison 2026 — Intrinsic Value Analysis

QNCX

Biological Products, (No Diagnostic Substances)

Quince Therapeutics, Inc.

Quality

4.3

out of 10

Value Trap

LOW

Price

$1.15

Last close

Models

8/13

Active

REPL

Biological Products, (No Diagnostic Substances)

Replimune Group, Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$8.69

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	QNCX Fair Value	QNCX Upside	REPL Fair Value	REPL Upside
Bayesian DCF	Intrinsic	$2.38	+106.7%	$1.76	-79.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	—	—	$2.22	-74.5%
Dynamic NAV	Asset-Based	$4.20	+265.0%	$3.58	-58.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for QNCX vs REPL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

QNCX vs REPL — Which Stock Is More Undervalued?

REPL scores higher with a 4.4/10 quality rating vs QNCX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Quince Therapeutics, Inc. (QNCX) and Replimune Group, Inc. (REPL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

QNCX currently trades at $1.15 with a QOC of 4.3/10, while REPL trades at $8.69 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).